The global economic burden of asthma and chronic obstructive pulmonary disease

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 1, 2016, Pages 11-23

  Ehteshami Afshar, S ^a   FitzGerald, J M ^b,c,d   Doyle Waters, M M ^d   Sadatsafavi, M ^b,c,d  

^a Faculty of Medicine   (Canada)

^b Ellis Hall   (Canada)

^c Institute for HEART+LUNG Health   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Asthma; COPD; Economic burden

Indexed keywords

ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; CAPITAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISABILITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; LIFE EXPECTANCY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; ECONOMICS; HEALTH;

ASTHMA; GLOBAL HEALTH; HEALTH EXPENDITURES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84952050613     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.15.0472     Document Type: Article

References (65)

1. FitzGerald J M, Poureslami I. The need for humanomics in the era of genomics and the challenge of chronic disease management. Chest 2014; 146: 10-12.
2. Beran D, Zar H J, Perrin C, Menezes A M, Burney P, Forum of International Respiratory Societies Working Group collaboration. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med 2015; 3: 159-170.
3. World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva, Switzerland: WHO, 2015. http://www.who.int/respiratory/copd/en/Accessed October 2015.
4. FitzGerald J M, Sadatsafavi M. The importance of measuring asthma control in emerging economies. Int J Tuberc Lung Dis 2014; 18: 254.
5. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478.
6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA, 2015: p 132 http://www.ginasthma.org/documents/4 Accessed October 2015.
7. Foster T S, Miller J D, Marton J P, Caloyeras J P, Russell M W, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD 2006; 3: 211-218.
8. Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani L G. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med 2011; 17 (Suppl 1): S35-S41.
9. Bahadori K, Doyle-Waters M M, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009; 9: 24.
10. Srivastava K, Thakur D, Sharma S, Punekar Y S. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoeconomics 2015; 33: 467-488.
11. Organisation for Economic Co-operation and Development. Purchasing power parities and exchange rates. Paris, France: OECD, 2015. http://stats.oecd.org/Index.aspx? DataSetCode=SNA-TABLE4 Accessed October 2015.
12. US Bureau of Labor Statistics. Archived Consumer Price Index Detailed Report Information. Washington DC, USA: Bureau of Labor Statistics, 2015. http://www.bls.gov/cpi/cpi-dr.htm Accessed October 2015.
13. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Oxford, UK: Oxford University Press, 2005.
14. Boccuzzi S J. Indirect Health Care Costs. In: Weintraub W S, ed. Cardiovascular health care economics. New York City, NY, USA: Humana Press, 2003. http://link.springer.com/chapter/10.1007/978-1-59259-398-95 Accessed October 2015.
15. Ernst R. Indirect costs and cost-effectiveness analysis. Value Health 2006; 9: 253-261.
16. Akobundu E, Ju J, Blatt L, Mullins C D. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006; 24: 869-890.
17. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United States. J Asthma 2009; 46: 73-80.
18. Maleki-Yazdi M R, Kelly S M, Lam S Y, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J 2012; 19: 319-324.
19. Accordini S, Corsico A G, Braggion M, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013; 160: 93-101.
20. Doz M, Chouaid C, Com-Ruelle L, et al. The association between asthma control, health care costs, and quality of life in France and Spain. BMC Pulm Med 2013; 13: 15.
21. Bavbek S, Mungan D, Türktas H, Misirlgil Z, Gemicioglu B, ADVISE Study Group. A cost-of-illness study estimating the direct cost per asthma exacerbation in Turkey. Respir Med 2011; 105: 541-548.
22. De Miguel-Díez J, Jimenez-Garćia R, Hernandez-Barrera V, et al. National trends in hospital admissions for asthma exacerbations among pediatric and young adult population in Spain (2002-2010). Respir Med 2014; 108: 983-991.
23. Barnett S B L, Nurmagambetov T A. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011; 127: 145-152.
24. Jang J, Gary Chan K C, Huang H, Sullivan S D. Trends in cost and outcomes among adult and pediatric patients with asthma: 2000-2009. Ann Allergy Asthma Immunol 2013; 111: 516-522.
25. Gold L S, Yeung K, Smith N, Allen-Ramey F C, Nathan R A, Sullivan S D. Asthma control, cost and race: results from a national survey. J Asthma 2013; 50: 783-790.
26. Ivanova J I, Bergman R, Birnbaum H G, Colice G L, Silverman R A, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012; 129: 1229-1235.
27. Bedouch P, Sadatsafavi M, Marra C A, FitzGerald J M, Lynd L D. Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study. PLOS ONE 2012; 7: e50949.
28. Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 2010; 17: 74-80.
29. Sadatsafavi M, Rousseau R, Chen W, et al. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. Chest 2014; 145: 787-793.
30. Alzaabi A, Alseiari M, Mahboub B. Economic burden of asthma in Abu Dhabi: a retrospective study. Clinicoecon Outcomes Res 2014; 6: 445-450.
31. Al-Busaidi N H, Habibullah Z, Soriano J B. The asthma cost in oman. Sultan Qaboos Univ Med J 2013; 13: 218-223.
32. Kim S-H, Kim T-W, Kwon J-W, et al. Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals. J Asthma 2012; 49: 303-309.
33. Lee Y-H, Yoon S-J, Kim E-J, Kim Y-A, Seo H-Y, Oh I-H. Economic burden of asthma in Korea. Allergy Asthma Proc 2011; 32: 35-40.
34. Kim C-Y, Park H-W, Ko S-K, et al. The financial burden of asthma: a nationwide comprehensive survey conducted in the republic of Korea. Allergy Asthma Immunol Res 2011; 3: 34-38.
35. Sun H-L, Lue K-H. Health care utilization and costs of adult asthma in Taiwan. Allergy Asthma Proc 2008; 29: 177-181.
36. Gold L S, Montealegre F, Allen-Ramey F C, Jardim J, Sansores R, Sullivan S D. Asthma control and cost in Latin America. Value Health Regional Issues 2014; 5: 25-28.
37. Short M E, Goetzel R Z, Pei X, et al. How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. J Occup Environ Med 2009; 51: 786-796.
38. Hutter N, Knecht A, Baumeister H. Health care costs in persons with asthma and comorbid mental disorders: a systematic review. Gen Hosp Psychiatry 2011; 33: 443-453.
39. Hemp P. Presenteeism: at work-but out of it. Harv Bus Rev 2004; 82: 49-58.
40. Andreasson W, Svensson K, Berggren F. The validity of the work productivity and activity impairment questionnaire for patients with asthma (WPAI-asthma): results from a web-based study. Value Health 2003; 6: 780.
41. Zhang W, Bansback N, Boonen A, Severens J L, Anis A H. Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. Value Health 2012; 15: 46-54.
42. Bateman E D, Boushey H A, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
43. Akazawa M, Halpern R, Riedel A A, Stanford R H, Dalal A, Blanchette C M. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 2008; 102: 1744-1752.
44. Nair K, Ghushchyan V, Van Den Bos J, et al. Burden of illness for an employed population with chronic obstructive pulmonary disease. Popul Health Manag 2012; 15: 267-275.
45. Ford E S, Murphy L B, Khavjou O, Giles W H, Holt J B, Croft J B. Total and state-specific medical and absenteeism costs of COPD among adults aged > 18 years in the United States for 2010 and projections through 2020. Chest 2015; 147: 31-45.
46. Pasquale M K, Sun S X, Song F, Hartnett H J, Stemkowski S A. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis 2012; 7: 757-764.
47. Mittmann N, Kuramoto L, Seung S J, Haddon J M, Bradley-Kennedy C, Fitzgerald J M. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med 2008; 102: 413-421.
48. Perera P N, Armstrong E P, Sherrill D L, Skrepnek G H. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD 2012; 9: 131-141.
49. Van Boven J F M, Vegter S, van der Molen T, Postma M J. COPD in the working age population: the economic impact on both patients and government. COPD 2013; 10: 629-639.
50. Dal Negro R W, Tognella S, Tosatto R, Dionisi M, Turco P, Donner C F. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes). Respir Med 2008; 102: 92-101.
51. Jensen M B, Fenger-Grøn M, Fonager K, Omland Ø, Vinding A L, Hansen J G. Chronic obstructive pulmonary disease involves substantial health care service and social benefit costs. Dan Med J 2013; 60: A4557.
52. Jansson S-A, Backman H, Stenling A, Lindberg A, Ronmark E, Lundback B. Health economic costs of COPD in Sweden by disease severity-has it changed during a ten years period? Respir Med 2013; 107: 1931-1938.
53. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009; 34: 850-857.
54. Miravitlles M, Garćia-Polo C, Domenech A, Villegas G, Conget F, de la Roza C. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung 2013; 191: 523-530.
55. Varol Y, Varol U, Baser Z, Usta L, Balci G, Ozacar R. The cost of COPD exacerbations managed in hospital. Turk Toraks Dergisi 2013; 14: 19-23.
56. Ozkaya S, Findik S, Atici A G. The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2011; 3: 15-18.
57. Kim C, Yoo K H, Rhee C K, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis 2014; 18: 737-743.
58. Van Manen J G, Bindels P J, IJzermans C J, van der Zee J S, Bottema B J, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001; 54: 287-293.
59. Soriano J B, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009; 374: 721-732.
60. Donaldson G C, Wedzicha J A. COPD exacerbations. 1: Epidemiology. Thorax 2006; 61: 164-168.
61. Pauwels R, Calverley P, Buist A S, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004; 98: 99-107.
62. Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol 2013; 13: 70-77.
63. Turner L, Shamseer L, Altman D G, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012; 11: MR000030.
64. Moher D, Liberati A, Tetzlaff J, Altman D G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264-269.
65. Wouters E F M. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97 (Suppl C): S3-S14.